Pneumococcal Vaccine Patient Education: What Pharmacists Should Know and Share

EP: 1.Epidemiology and High-Risk Populations for Pneumococcal Disease

EP: 2.Comparing Pneumococcal Vaccines and CDC Recommendations for Adults

EP: 3.Updated Evidence-Based Recommendations for Pneumococcal Conjugate Vaccines

EP: 4.Pharmacist’s Guide: Choosing the Most Appropriate Pneumococcal Vaccine for Patients

EP: 5.Risk vs. Benefit of Pneumococcal Vaccines: Shared Clinical Decision-Making for Patients and Pharmacists

Now Viewing

EP: 6.Pneumococcal Vaccine Patient Education: What Pharmacists Should Know and Share

Pneumococcal Vaccine Patient Education: What Pharmacists Should Know and Share Summary

Pharmacists must provide comprehensive patient education on pneumococcal vaccines, including proper administration of vaccine information statements (VIS) as required by law for most adult vaccines. The pneumococcal VIS documents were recently updated on May 29, 2025, with separate versions for conjugate vaccines (grouped together) and polysaccharide vaccines. Pharmacists should verify they are using the most current versions by checking the date on the back of the form and provide patients with either paper copies or QR code access. Regarding adverse effects, pneumococcal vaccines have demonstrated excellent safety profiles through years of use and extensive post-marketing surveillance, with very few identified risks. Common expected reactions include injection site pain, swelling, and tenderness, along with possible headache, fatigue, and muscle aches lasting one to two days. Pharmacists should explain that these symptoms indicate the immune system is responding appropriately and generating acquired immunity.

Comprehensive pre-vaccination screening is essential for preventing serious adverse reactions and ensuring patient safety. Since pneumococcal vaccines are inactivated, screening requirements are streamlined compared to live vaccines, focusing on moderate to severe acute illness, allergies or serious reactions to vaccine components, and history of fainting or vaccine anxiety. While patients with fainting histories can still receive vaccination, pharmacists must modify their approach to protect the patient during the procedure. Important allergen considerations include the absence of latex in all discussed pneumococcal products, though the three conjugate vaccines contain yeast, which represents a rare but potential allergy concern for some patients.

The screening process requires thorough attention to detail, as experienced providers may occasionally rush through routine assessments and miss critical information. Pharmacists should actively read screening questions aloud to patients rather than relying solely on self-completed forms, ensuring patients understand each question and provide accurate responses. Specific attention should be paid to components beyond common allergens, such as diphtheria toxoid present in conjugate vaccines. This transparent screening approach minimizes risks, identifies potential concerns early, empowers patients through education, and ultimately maximizes both the safety and effectiveness of pneumococcal vaccination programs.